Format

Send to

Choose Destination
See comment in PubMed Commons below
Cardiovasc Ther. 2012 Aug;30(4):e174-82. doi: 10.1111/j.1755-5922.2011.00263.x. Epub 2011 Feb 17.

TRITON and beyond: new insights into the profile of prasugrel.

Author information

  • 1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA. joseph@lilly.com

Abstract

Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38). This article reviews and discusses select components of a large literature of prasugrel data that has emerged since the TRITON-TIMI 38 (TRITON) study primary disclosure.

© 2011 Blackwell Publishing Ltd.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Write to the Help Desk